RLMD · Relmada Therapeutics, Inc. · Stock research

Current Thesis

The pivot worked and the market already paid for it. Relmada spent 2022–2025 as a discredited depression shell after REL-1017 missed, then reinvented itself around NDV-01, a controlled-release intravesical gemcitabine/docetaxel formulation for non-muscle-invasive bladder cancer. Twelve-month Phase 2 interim data 76% complete response at 12 months in high-risk patients, 80% in the BCG-unresponsive cohort, 95% complete response at any time, zero grade 3+ treatment-related adverse events plus a $160.0M PIPE at $4.75 in March 2026 took the stock from a $0.55 52-week low to an $8.00 high. That leg is finished.

What the tape is doing now matters more than the story. RLMD fell 10.5% on 2026-07-16 (from a $6.21 close to a $5.52 low) on the day it announced its Q2 earnings date, then another 4.0% on 2026-07-17 to $5.24. A double-digit drawdown on a scheduling press release is not news-driven; it reads as the June Russell 2000/3000 reconstitution bid exhausting itself with nothing behind it. The company sits ~35% below its 52-week high with $234M of cash, a guided runway through 2029, six analysts at Strong Buy against a $12.67 average target and no dated clinical event until initial 3-month pathway-2 RESCUE results at the end of 2026. That gap between narrative quality and calendar emptiness is the whole problem. This is a good story with no near-term forcing function and a broken price structure, which is how post-re-rate biotechs bleed for two quarters.

Bullish and bearish views on Relmada Therapeutics, Inc.

The model's bull view on Relmada Therapeutics, Inc. (RLMD), in brief: NDV-01 Phase 2 12-month interim (reported 2026, presented at the Society for Urologic Oncology and updated at AUA): 76% CR at 12 months in high-risk NMIBC, 80% CR in BCG-unresponsive, 95% CR at any time, no progression to muscle-invasive disease, no radical cystectomies. The bear view: Two sessions, roughly 15% down, on a press release announcing an earnings date. Both cases follow in full.

Bull Case

• NDV-01 Phase 2 12-month interim (reported 2026, presented at the Society for Urologic Oncology and updated at AUA): 76% CR at 12 months in high-risk NMIBC, 80% CR in BCG-unresponsive, 95% CR at any time, no progression to muscle-invasive disease, no radical cystectomies. In BCG-unresponsive disease the alternative is bladder removal, so durable CR is the entire commercial argument.
• Safety profile is the underrated datapoint: no grade 3 or higher treatment-related adverse events, no treatment interruptions or discontinuations over 12 months. Against an approved competitive set with real tolerability burdens, that supports an adjuvant intermediate-risk expansion where the bar for tolerability is much higher.
• FDA has aligned on the registrational design. The Phase 3 RESCUE program carries two independent approval pathways 2L BCG-unresponsive and adjuvant intermediate-risk from one molecule, guided to initiate mid-2026 with initial 3-month pathway-2 results by end-2026.
• Balance sheet is genuinely fixed. $234M cash at Q1 2026 following the March PIPE (29,474,569 shares at $4.75 plus 4,210,527 pre-funded warrants, $160.0M gross, closed 2026-03-12), guided to fund operations through 2029 including RESCUE completion. Against a ~$550M market cap at $5.24, enterprise value is roughly $315M for two Phase-2 assets.
• Sell-side is re-forming from zero: H.C. Wainwright initiated Buy with a $12 target in late June 2026; consensus across six analysts is Strong Buy at a $12.67 average with a $9–$19 range. Coverage this thin means new initiations are still additive rather than crowded.
• Sepranolone is a free option. The GABA-A modulator acquired from Asarina Pharma in February 2025 is guided into a Phase 2 in Prader-Willi syndrome mid-2026, with Tourette syndrome behind it an unpriced second shot in a rare-disease indication with no approved competition for hyperphagia-driven compulsivity.
• April 2026 USPTO provisional filing covering NDV-01 formulations and methods extends protection toward 2047, which is the answer to the "it's just generic chemo in a tube" objection.

Bear Case

• Two sessions, roughly 15% down, on a press release announcing an earnings date. That is distribution. The stock closed $5.24 on 2026-07-17 having lost every level from the $6.20s, and the only structural support left is the $4.75 PIPE price about 9% lower.
• The catalyst calendar is empty. Phase 2 data is out, the PIPE is closed, sell-side has initiated, Russell inclusion has happened. Everything that could re-rate this name in 2026 has already fired except an end-of-year 3-month readout that is five months away and, at three months of follow-up, will not be definitive.
• NMIBC is contested by better-capitalized programs: J&J's TAR-200, CG Oncology's cretostimogene, and ImmunityBio's already-approved Anktiva. NDV-01's differentiation is delivery economics on an established generic backbone. That is a pharmacoeconomic argument, and pharmacoeconomic arguments do not command scarcity premiums.
• The Phase 2 is single-arm, small, and run in Israel. A 95% any-time CR rate in an uncontrolled study is exactly the kind of number that regresses in a randomized registrational setting; the market has capitalized it as though it will not.
• The October 13, 2022 REL-1017 RELIANCE II failure took the stock from roughly $27 to ~$4.50 intraday and erased ~84% of market cap. Same management, same board, and a new therapeutic area they had no prior operating history in.
• An effective S-3 shelf remains on file. Cash through 2029 removes the necessity of a raise but not the temptation biotechs with a 14x move off the lows and a funded Phase 3 routinely opportunistically upsize, and the March PIPE showed this board will issue.
• Beta to XBI runs roughly 1.5–2x. A single-name thesis does not survive a rolling biotech tape.

Setup & Price Structure

The chart is the reason to stand aside. RLMD ran from a $0.55 52-week low to an $8.00 high, then failed, and the last two sessions (-10.5% on 2026-07-16, -4.0% on 2026-07-17 to $5.24) took out the consolidation shelf on 3.24M shares. That is roughly 35% off the high with each bounce making a lower high.

Three levels define the map. $8.00 is the 52-week high and the measuring stick for any renewed leg. $6.21 the 2026-07-15 close is now overhead supply that any recovery has to reclaim on volume before the structure is repairable. $4.75 is the March PIPE clearing price, where a large block of institutional stock was placed; that is the level the whole post-pivot re-rate is anchored to, and it sits only 9% below spot.

Price is now below the analyst target band's entire range ($9–$19), which in a healthy setup would read as opportunity and here reads as sell-side lagging the tape by three weeks. The honest characterisation of the theme is MATURING rolling toward stalled: the oncology-pivot story is fully published, the sell-side has arrived, the index funds have bought, and there is nothing left to surprise with until December. Fresh buying here is catching a knife into an empty calendar, and the specific trap on offer is the cheap-relative-to-PT one adding on weakness because a $12.67 consensus makes $5.24 look like 141% upside. The $4.75 line either holds and produces a base worth buying, or it doesn't and the trade was never there.

Catalyst Calendar (next 30 days)

• 2026-08-06, 4:30pm ET (confirmed) Q2 2026 financial results and business update. Watch for: whether the Phase 3 RESCUE first-patient-dosed announcement has actually landed (guided mid-2026, currently unconfirmed), cash balance versus the $234M Q1 figure and implied quarterly burn, and any change to the end-2026 pathway-2 3-month readout timing. This is a timing-and-burn print, not a value event.
• ~2026-08-06 (est.) Q2 10-Q filing alongside results. The line to read is shelf activity and any ATM usage since March.
• Mid-2026, undated Phase 3 RESCUE initiation announcement (2L BCG-unresponsive and adjuvant intermediate-risk pathways). Every week past July without an 8-K on this is a small mark against management credibility on guidance.
• Mid-2026, undated Sepranolone Phase 2 initiation in Prader-Willi syndrome.
• End-2026 (guided) initial 3-month results from RESCUE registrational pathway 2. The only genuine re-rating event on the visible calendar, and it is outside this window.

What Would Change Our Mind

The bearish structural read flips on a weekly close back above $6.21 on above-average volume, reclaiming the shelf that broke on 2026-07-16, ideally paired with a dated RESCUE first-patient-dosed 8-K. That combination converts an empty calendar into a live program and re-establishes higher lows.

It flips harder on any of: a RESCUE enrollment-completion or interim-timing acceleration that pulls registrational data into H1 2027; a partnership or licensing deal that validates NDV-01's commercial economics against TAR-200 and cretostimogene with a third party's capital; or clean Phase 2 data extending durability beyond 12 months in the BCG-unresponsive cohort.

The thesis breaks on a weekly close below $4.75, which would mean the March PIPE buyers are underwater and the institutional anchor for the pivot narrative has failed. It also breaks on RESCUE slipping out of 2026 entirely, on the FDA-aligned registrational design changing, on any capital raise below the PIPE price, or on a competitor readout in BCG-unresponsive NMIBC that makes NDV-01's delivery-economics pitch commercially irrelevant.

Correlation Notes

• XBI / biotech beta: RLMD moves at roughly 1.5–2x XBI. In a risk-off biotech tape, the single-name story is noise. Any read on this name needs XBI's own trend checked first.
• NMIBC competitive complex: J&J (TAR-200), CG Oncology (CGON, cretostimogene), ImmunityBio (IBRX, Anktiva). Positive readouts from these names are a direct negative for NDV-01's addressable share, unlike most oncology comps where a peer win validates the mechanism.
• Russell 2000 / small-cap flow: the June 2026 index addition means RLMD now carries passive small-cap beta it did not have in Q1, which cuts both ways mechanical bid on inflows, mechanical supply on rebalances and outflows. The July 16-17 break is consistent with the post-reconstitution unwind.
• Post-PIPE biotech cohort: names that placed large blocks in Q1 2026 and re-rated hard tend to trade together as lockup and registration-statement milestones cycle through. Watch the group, not the ticker in isolation.
• Rate sensitivity: a pre-revenue developer with a 2029 runway and no cash flows until the 2030s is duration in equity form. Long-end yield moves hit the discount rate on the entire NPV directly.